Jakob Loven, Ph.D., is a Managing Partner at Nextech Invest with over 20 years of experience in cancer research and translational medicine. An accomplished oncology-focused entrepreneur and life science venture capitalist, Jakob has extensive experience in creating, launching and building early stage therapeutic-focused biotechnology companies and was a co-founder of Relay Therapeutics (NASDAQ: RLAY) and Syros Pharmaceuticals (NASDAQ: SYRS).
Jakob currently serves as a board director of A2 Biotherapeutics, Arrakis, Kronos (NASDAQ: KRON), Vividion and is a board observer of Kinnate Biopharma (NASDAQ: KNTE). He is a former board member or observer of Arvinas (NASDAQ: ARVN), Turning Point Therapeutics (NASDAQ: TPTX) and Autolus (NASDAQ: AUTL).
Jakob holds a B.A. in Biomedical Sciences from the UK, earned his Ph.D. in Medical Sciences focused on oncology from the Karolinska Institute, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research (WIBR) and Massachusetts Institute of Technology (MIT).